11:14:14 EDT Fri 12 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Z:BMY - BRISTOL-MYERS SQUIBB CO - http://www.bristolmyers.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMY - Z0.740.75·40.760.340.755+0.0050.03,663.3147,91715,58241.09  41.14  40.3665.375  39.3510:58:02Jul 0815 min RT 2¢

Recent Trades - Last 10 of 15582
Time ETExPriceChangeVolume
10:58:12Z40.745-0.00555
10:58:12Z40.745-0.0053
10:58:11Z40.745-0.005100
10:58:11Z40.745-0.00518
10:58:10Z40.745-0.0051
10:58:08Z40.7401-0.0099245
10:58:07Z40.745-0.005100
10:58:06Z40.745-0.00525
10:58:05Z40.7495-0.000515
10:58:04Z40.7375-0.0125100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-08 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
2024-06-28 15:41U:BMYNews ReleaseBristol Myers Squibb Named to Dow Jones Sustainability Index North America
2024-06-21 19:30U:BMYNews ReleaseBristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(TM) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
2024-06-21 06:59U:BMYNews ReleaseEuropean Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
2024-06-20 06:59U:BMYNews ReleaseBristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
2024-06-18 16:16U:BMYNews ReleaseBristol Myers Squibb Elects Michael R. McMullen to Board of Directors
2024-06-18 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Dividend
2024-06-17 09:45U:BMYNews ReleaseAcute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
2024-06-13 16:46U:BMYNews ReleaseU.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
2024-06-04 08:00U:BMYNews ReleaseBristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
2024-06-04 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-06-03 10:13U:BMYNews ReleaseBristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(TM) Annual Meeting
2024-06-03 08:00U:BMYNews ReleaseBristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(TM) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
2024-06-01 08:00U:BMYNews ReleaseKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
2024-05-30 11:51U:BMYNews ReleaseU.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
2024-05-29 09:57U:BMYNews ReleaseASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
2024-05-29 06:59U:BMYNews ReleaseBristol Myers Squibb Receives European Commission Approval for Opdivo(TM) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2024-05-28 10:17U:BMYNews ReleaseASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
2024-05-23 17:05U:BMYNews ReleaseBristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
2024-05-23 06:59U:BMYNews ReleaseBristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting